Efficacy and safety of eflapegrastim confirmed in reducing severe neutropenia in breast cancer patients treated with myelosuppressive chemotherapy in the second Phase 3 randomized controlled multinational trial compared to pegfilgrastim (RECOVER trial)

被引：0
|
作者：
Schwartzberg, L.
Bhat, G.
Mezei, K.
Lang, I.
Moon, Y. W.
Senviratne, L.
Chawla, S.
Cobb, P.
Yang, Z.
机构：
[1] West Canc Ctr, Germantown, TN USA
[2] Spectrum Pharmaceut, Irvine, CA USA
[3] Szabolcs Szatmar Bereg Megyei Korhazak & Egyet Ok, Onkol Osztaly, Nyiregyhaza, Hungary
[4] Orszagos Onkol Int, Belgyogyaszati Onkol Osztaly B, Budapest, Hungary
[5] Cha Bundang Med Ctr, Seongnam, South Korea
[6] Los Angeles Hematol & Oncol Med Grp, Los Angeles, CA USA
[7] St Vincent Frontier Canc Ctr, Billings, MT USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P1-13-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-13-05
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of eflapegrastim in reducing severe neutropenia in patients treated with myelosuppressive chemotherapy in a phase 3 randomized controlled trial compared to pegfilgrastim (ADVANCE trial).
    Schwartzberg, Lee Steven
    Yang, Zandong
    Peguero, Julio Antonio
    Agajanian, Richy
    Bharadwaj, Jayaram S.
    Restrepo, Alvaro
    Hlalah, Osama
    Mehmi, Inderjit
    Bhat, Gajanan
    Cobb, Patrick Wayne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A randomized, multicenter clinical trial to determine the efficacy and safety of pegfilgrastim (GEMA BIOTECH) compared to pegfilgrastim (Roche) for prevention of chemotherapy induced neutropenia in patients with breast cancer.
    Eduardo Richardet, Martin
    Dario Kowalyszyn, Ruben
    Susana Varela, Mirta
    Ortiz, Eduardo
    Micheri, Cristian
    Jose Zarba, Juan
    Kahl, Susana
    Klimovsky, Ezequiel
    Alicia Federico, Andrea
    Enrique Fein, Luis
    Horacio Cassini, Jorge
    Cortese, Gustavo
    Visintini Jaime, Florencia
    Cordeiro, Lucas
    Ruben Lago, Nestor
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
    Cobb, Patrick Wayne
    Moon, Yong Wha
    Mezei, Klara
    Lang, Istvan
    Bhat, Gajanan
    Chawla, Shanta
    Hasal, Steven J.
    Schwartzberg, Lee S.
    CANCER MEDICINE, 2020, 9 (17): : 6234 - 6243
  • [4] Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial
    Xu, Fengrui
    Zhang, Yang
    Miao, Zhanhui
    Zeng, Xiaohua
    Wu, Biao
    Cai, Li
    Liu, Jinping
    Wang, Shusen
    Hu, Iachun
    Zheng, Wenbo
    Chen, Zhiyue
    Yang, Qing
    Jiang, Zefei
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [5] Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Bondarenko, Igor
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    BMC CANCER, 2013, 13
  • [6] Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
    Igor Bondarenko
    Oleg A Gladkov
    Reiner Elsaesser
    Anton Buchner
    Peter Bias
    BMC Cancer, 13
  • [7] Eflapegrastim versus Pegfilgrastim for Chemotherapy-Induced Neutropenia in Korean and Asian Patients with Early Breast Cancer: Results from the Two Phase III ADVANCE and RECOVER Studies
    Moon, Yong Wha
    Kim, Seung Ki
    Lee, Keun Seok
    Lee, Moon Hee
    Park, Yeon Hee
    Park, Kyong Hwa
    Kim, Gun Min
    Lim, Seungtaek
    Lee, Seung Ah
    Choi, Jae Duk
    Baek, Eunhye
    Han, Hyesun
    Baek, Seungjae
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 766 - 777
  • [8] Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
    Morand, Eric
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian
    Askanase, Anca
    Riche'z, Christophe
    Bae, Sang-Cheol
    Brohawn, Philip
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [9] EFFICACY AND SAFETY OF ANIFROLUMAB IN PATIENTS WITH MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF THE SECOND PHASE 3 RANDOMIZED CONTROLLED TRIAL
    Morand, Eric F.
    Furie, Richard
    Tanaka, Yoshiya
    Bruce, Ian N.
    Askanase, Anca D.
    Richez, Christophe
    Bae, Sang-Cheol
    Brohawn, Mr Philip Z.
    Pineda, Lilia
    Berglind, Anna
    Tummala, Raj
    INTERNAL MEDICINE JOURNAL, 2020, 50 : 22 - 23
  • [10] Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
    Waller, Cornelius F.
    Ranganna, Gopinath M.
    Pennella, Eduardo J.
    Blakeley, Christopher
    Bronchud, Miguel H.
    Mattano, Leonard A., Jr.
    Berzoy, Oleksandr
    Voitko, Nataliia
    Shparyk, Yaroslav
    Lytvyn, Iryna
    Rusyn, Andriy
    Popov, Vasil
    Lang, Istvan
    Beckmann, Katrin
    Sharma, Rajiv
    Baczkowski, Mark
    Kothekar, Mudgal
    Barve, Abhijit
    ANNALS OF HEMATOLOGY, 2019, 98 (05) : 1217 - 1224
12345